Lumida
/FATE
⌘K
Fate Therapeutics Inc

Fate Therapeutics Inc

FATE
$2.31USD↓-0.86%-0.02 today

MARKET CAP

276.8M

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$2 – $2

52W RANGE

$1
$3

AI Summary

Stalk
Buy NowMedium

Stock is in a Stage 2 uptrend medium-term bullish environment, showing a pullback into rising EMAs that have held support, offering a timely buy opportunity despite a Bullish Exhaustion pattern that signals possible short-term fatigue.

  • ↑RECLAIM-LN Phase 2 trial for FT819 in SLE launched; first patient dosed.
  • ↑$153.8M cash as of June 30 2026 funds operations into 2028.
  • ↓Q2 2026 net loss $30M and EPS –$0.25 reflect ongoing losses.
Full analysis →

Buying

7

institutions

Selling

4

institutions

New Positions

3

this quarter

Filing Period

Q2 2026

latest 13-F

13-F Holdings

Institution↕Action↕Shares Held↕Value↓Change↕Chg %↕Weight↕
BI

Blackrock, Inc.

Q2 2026

SELL7.30 M19.71 M+-2.77 M+63.1%0.00%
AC

Aqr Capital Management LLC

Q2 2026

BUY3.84 M10.36 M+835.71 K+187.7%0.00%
RT

Renaissance Technologies LLC

Q2 2026

BUY2.98 M8.05 M+8.59 K+125.7%0.01%
MM

Millennium Management LLC

Q2 2026

BUYNEW2.43 M6.57 M+2.43 M+0.0%0.00%
CA

Citadel Advisors LLC

Q2 2026

BUY1.09 M2.95 M+123.38 K+153.6%0.00%
TR

T. Rowe Price Investment Management, Inc.

Q2 2026

BUYNEW1.08 M2.92 M+1.08 M+0.0%0.00%
PA

Point72 Asset Management, L.P.

Q2 2026

BUY442.23 K1.19 M+399.11 K+2207.6%0.00%
MG

Man Group Plc

Q2 2026

SELL176.11 K475.49 K+-253.97 K-7.9%0.00%
WP

Woodline Partners LP

Q2 2026

SELL159.65 K431.06 K+-317.65 K-24.7%0.00%
BA

Balyasny Asset Management L.P.

Q2 2026

BUYNEW13.41 K36.22 K+13.41 K+0.0%0.00%
JC

Jpmorgan Chase & Co

Q2 2026

SELL9.00 K21.77 K+-35.89 K-57.1%0.00%